Secondary Exposure of Family Members to Cyclophosphamide After Chemotherapy of Outpatients With Cancer: A Pilot Study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Althouse, R., Huff, J., Tomatis, L., & Wilbourn, J. (1979). Chemicals and industrial processes associated with cancer in humans (IARC Monographs, Vol. 1–20). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Supplement, 1, 1–71.
American Society of Hospital Pharmacists. (1990). ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. American Journal of Hospital Pharmacy, 47, 1033–1049.
Burgaz, S., Karahalil, B., Canli, Z., Terzioglu, F., Ancel, G., & Anzion, R.B. (2002). Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Human and Experimental Toxicology, 21, 129–135. doi:10.1191/0960327102ht230oa
Cardonick, E., & Iacobucci, A. (2004). Use of chemotherapy during human pregnancy. Lancet Oncology, 5, 283–291. doi:10.1016/S1470 -2045(04)01466-4
Fransman, W., Roeleveld, N., Peelen, S., de Kort, W., Kromhout, H., & Heederik, D. (2007). Nurses with dermal exposure to antineoplastic drugs: Reproductive outcomes. Epidemiology, 18, 112–119. doi:10.1097/01.ede.0000246827.44093.c1
Fransman, W., Vermeulen, R., & Kromhout, H. (2005). Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. International Archives of Occupational and Environmental Health, 78, 403–412. doi:10.1007/s00420-004-0595-1
Hedmer, M., Tinnerberg, H., Axmon, A., & Jonsson, B.A. (2008). Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. International Archives of Occupational and Environmental Health, 81, 899–911. doi:10.1007/s00420-007-0284-y
Hemminki, K., Kyyronen, P., & Lindbohm, M.L. (1985). Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. Journal of Epidemiology and Community Health, 39, 141–147. doi:10.1136/jech.39.2.141
Hon, C.Y., Teschke, K., Demers, P.A., & Venners, S. (2014). Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Annals Occupational Hygiene, 58, 761–770. doi:10.1093/annhyg/meu019
International Agency for Research on Cancer. (2013). IARC monographic on the evaluation of the carcinogenic risk: The IARC monographs, volumes 1-109. Retrieved from http://monographs.iarc.fr/ENG/Classification/
Kusnetz, E., & Condon, M. (2003). Acute effects from occupational exposure to antineoplastic drugs in a para-professional health care worker. American Journal of Industrial Medicine, 44, 107–109. doi:10.1002/ajim.10230
Mader, R.M., Rizovski, B., Steger, G.G., Wachter, A., Kotz, R., & Rainer, H. (1996). Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Archives of Environmental Health, 51, 310–314. doi:10.1080/00039896.1996.9936030
McDiarmid, M.A., Oliver, M.S., Roth, T.S., Rogers B., & Escalante, C. (2010). Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. Journal of Occupational and Environmental Medicine, 52, 1028–1034. doi:10.1097/JOM.0b013e3181f73ae6
Meijster, T., Fransman, W., Veldhof, R., & Kromhout, H. (2006). Exposure to antineoplastic drugs outside the hospital environment. Annals of Occupational Hygiene, 50, 657–664. doi:10.1093/annhyg/mel023
Meirow, D., & Schiff, E. (2005). Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. Journal of the National Cancer Institute. Monographs, 34, 21–25. doi:10.1093/jncimonographs/lgi025
Nygren, O., & Lundgren, C. (1997). Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. International Archives of Occupational and Environmental Health, 70, 209–214. doi:10.1007/s004200050209
Occupational Safety and Health Administration. (1995). OSHA technical manual: Controlling occupational exposure to hazardous drugs (Occupational Safety and Health Administration, Section 6, Ch. 2). Retrieved from www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., & Carbone, P.P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649–655. doi:10.1097/00000421-198 212000-00014
Pethran, A., Schierl, R., Hauff, K., Grimm, C.H., Boos, K.S., & Nowak, D. (2003). Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: Monitoring of urinary concentrations. International Archives of Occupational and Environmental Health, 76, 5–10.
Polovich, M. (2011). Safe handling of hazardous drugs (2nd ed.). Pittsburgh, PA: Oncology Nursing Society.
Sessink, P.J., Anzion, R.B., Van den Broek, P.H., & Bos, R.P. (1992). Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharmaceutisch Weekblad Scientific Edition, 14, 16–22. doi:10.1007/BF01989220
Sessink, P.J., Boer, K.A., Scheefhals, A.P., Anzion, R.B., & Bos, R.P. (1992). Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. International Archives of Occupational and Environmental Health, 64, 105–112. doi:10.1007/bf00381477
Sessink, P.J., Kroese, E.D., van Kranen, H.J., & Bos, R.P. (1995). Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. International Archives of Occupational and Environmental Health, 67, 317–323. doi:10.1007/BF00385647
Sessink, P.J., Scholtes, M.M., Anzion, R.B., & Bos, R.P. (1993). Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. Journal of Chromatography, 616, 333–337. doi:10.1016/0378-4347(93)80404-R
Skov, T., Lynge, E., Maarup, B., Olsen, J., Rorth, M., & Winthereik, H. (1990). Risks for physicians handling antineoplastic drugs. Lancet, 336, 1446. doi:10.1016/0140-6736(90)93148-i
Walusiak, J., Wittczak, T., Ruta, U., & Palczynski, C. (2002). Occupational asthma due to mitoxantrone. Allergy, 57, 461.
Wick, C., Slawson, M.H., Jorgenson, J.A., & Tyler, L.S. (2003). Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health-System Pharmacy, 60, 2314–2320.